Thus, loss of C/EBPβ-mediated gene activation of Cdkn2b, as well as Cdh1 and Cxadr, shifts the TGF-β response in breast cancer cells from growth inhibition to EMT. The gene discussed is CDKN2B; the disease is breast cancer.